Health

BONESUPPORT’s FDA Authorized CERAMENT® G to be featured at Orthopedic Trauma Association Annual Meeting (OTA)

Leave a comment


News Image

During the conference, BONESUPPORT is sharing insights from a new study on the long-term effectiveness of its CERAMENT® G technology, the first and only injectable combination antibiotic bone graft substitute that recently received market authorization from the US Food and Drug Administration (FDA).


TAMPA, Fla. (PRWEB)

This week, BONESUPPORT, an emerging leader in orthobiologics, is attending the Orthopedic Trauma Association (OTA) annual meeting in Tampa, Florida. OTA is bringing together more than 400 accomplished orthopedic trauma surgeon presenters/moderators/authors who are sharing their expertise and experience, including delivering cutting-edge research findings and unique multi-national treatment perspectives. During the conference, BONESUPPORT is sharing insights from a new study on the long-term effectiveness of its CERAMENT® G technology, the first and only injectable combination antibiotic bone graft substitute that recently received market authorization from the US Food and Drug Administration (FDA).

Conducted at Oxford University Hospitals, the significant study followed 100 consecutive patients and found that with the use of CERAMENT G, 94% were infection free at a mean follow-up of six years. It also showed a 3% fracture rate with no further pathologic fractures beyond the first year after surgery.

“This study is completely unique, as it is the first time a comprehensive analysis was completed with such a strict protocol – and the results are powerful,” said Emil Billbaeck, CEO of BONESUPPORT. “This study showcases the efficacy of our technology for reducing infection and provides another solid proof point of the significant difference our bone remodeling capabilities make for patients and clinicians alike.”

No other bone graft company has invested in such sophisticated research as BONESUPPORT

BONESUPPORT’s OTA Schedule

Friday, October 14, 2022:

  • -What: Breakfast Symposium featuring Prof. Martin McNally, who will present on the challenges of fracture related infections and share the Oxford experience, including mid-long term results with CERAMENT® G – the first & only FDA-authorized injectable antibiotic-eluting bone graft substitute by BONESUPPORT™

  • -When: 7:00 – 7:50 a.m. ET

  • -Where: Room 118

Friday, October 14:

  • -What: Annual Foot and Ankle meeting: “How Do Treatment Methods Affect Outcome of Surgery for Fracture-Related Infection?” featuring presenting author: Martin McNally, MD, MBCHB (Bone Infection Unit)

  • -When: 4:31 – 4:37 p.m. ET

  • -Where: West Exhibit Hall

For more information about the company and its groundbreaking approach, visit http://www.bonesupport.com.

About BONESUPPORT

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to demonstrate further the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Share article on social media or email:

Leave a Reply